Skip to content
Metaxalone
Skelaxin (metaxalone) is a small molecule pharmaceutical. Metaxalone was first approved as Skelaxin on 1982-01-01. It is used to treat muscle cramp, muscle rigidity, muscle spasticity, myositis, and pain amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
Skelaxin (generic drugs available since 2010-03-31)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Metaxalone
Tradename
Company
Number
Date
Products
SKELAXINKing PharmaceuticalsN-013217 RX2002-08-30
1 products, RLD, RS
METAXALONEPrimus PharmaceuticalsN-022503 RX2015-06-01
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
metaxaloneANDA2023-06-12
skelaxinNew Drug Application2015-03-19
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
muscle crampHP_0003394D009120—
muscle rigidityHP_0002063D009127—
muscle spasticityHP_0001257D009128—
myositisEFO_0000783D009220G72.49
painEFO_0003843D010146R52
spasm—D013035M62.83
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Metaxalone, Skelaxin, King Pharms
71225662026-02-06U-915
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
StrokeD020521EFO_0000712I63.9—11——1
Transient ischemic attackD002546EFO_0003764G45.9—11——1
Patent foramen ovaleD054092HP_0001655Q21.12—11——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMETAXALONE
INNmetaxalone
Description
Metaxalone is an aromatic ether.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1cc(C)cc(OCC2CNC(=O)O2)c1
Identifiers
PDB—
CAS-ID1665-48-1
RxCUI59078
ChEMBL IDCHEMBL1079604
ChEBI ID6797
PubChem CID15459
DrugBankDB00660
UNII ID1NMA9J598Y (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Skelaxin - Amneal Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Skelaxin - Elan Corporation
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Skelaxin - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 232 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,338 adverse events reported
View more details